Onco Wiki / Regimen

Carboplatin + Paclitaxel (ovarian 3-weekly)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsDRUG-CARBOPLATIN DRUG-PACLITAXEL
IDREG-CARBO-PACLI-OVARIAN
TypeRegimen
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025

Notes

Backbone of advanced ovarian 1L for ~25 years. ICON-7 + GOG-218 added bevacizumab to induction + maintenance — maintenance bev improves PFS but not OS (selected stage III suboptimally debulked + stage IV benefit). Weekly dose-dense Pacli (JGOG-3016) PFS superior vs 3-weekly in Asian-population trial; not consistently reproduced in Western GOG-262 / ICON-8.

Used By

Handbook Chapters

Indication